SE378110B - - Google Patents

Info

Publication number
SE378110B
SE378110B SE7206645A SE664572A SE378110B SE 378110 B SE378110 B SE 378110B SE 7206645 A SE7206645 A SE 7206645A SE 664572 A SE664572 A SE 664572A SE 378110 B SE378110 B SE 378110B
Authority
SE
Sweden
Application number
SE7206645A
Inventor
R L Brattsand
K G Claeson
Af Ekenstam B Thuresson
B A Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Priority to SE7206645A priority Critical patent/SE378110B/xx
Priority to IL42154A priority patent/IL42154A/en
Priority to ZA732956A priority patent/ZA732956B/xx
Priority to AU55252/73A priority patent/AU478324B2/en
Priority to DE2323216A priority patent/DE2323216C3/de
Priority to CY1012A priority patent/CY1012A/xx
Priority to GB2219573A priority patent/GB1428416A/en
Priority to FI731543A priority patent/FI50711C/fi
Priority to US359913A priority patent/US3928326A/en
Priority to DK277073A priority patent/DK133249C/da
Priority to CA171,781A priority patent/CA1003402A/en
Priority to FR7318126A priority patent/FR2185406B1/fr
Priority to BE131271A priority patent/BE799728A/xx
Priority to SU1918554A priority patent/SU468408A3/ru
Priority to NLAANVRAGE7306979,A priority patent/NL175917C/xx
Priority to JP5623473A priority patent/JPS547794B2/ja
Publication of SE378110B publication Critical patent/SE378110B/xx
Priority to US05/629,390 priority patent/US3992534A/en
Priority to US05/629,493 priority patent/US3996359A/en
Priority to KE2969A priority patent/KE2969A/xx
Priority to HK490/79A priority patent/HK49079A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SE7206645A 1972-05-19 1972-05-19 SE378110B (en:Method)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (en:Method) 1972-05-19 1972-05-19
IL42154A IL42154A (en) 1972-05-19 1973-05-01 Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby
ZA732956A ZA732956B (en) 1972-05-19 1973-05-01 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
AU55252/73A AU478324B2 (en) 1972-05-19 1973-05-04 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
DE2323216A DE2323216C3 (de) 1972-05-19 1973-05-09 Verfahren zur Auftrennung von Stereoisomerengemischen von Pregna-1,4dien-11 -ol-33-dionen
CY1012A CY1012A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby
GB2219573A GB1428416A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby
FI731543A FI50711C (fi) 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.
US359913A US3928326A (en) 1972-05-19 1973-05-14 Process for the separation of stereoisomeric mixtures into their components and components obtained hereby
DK277073A DK133249C (da) 1972-05-19 1973-05-17 Fremgangsmade til opspaltning af stereoisomerblandinger af 16alfa,17alfa-alkylidendioxypregnan-11beta,21-diol-3,20-dioner
CA171,781A CA1003402A (en) 1972-05-19 1973-05-18 Process for the separation of steroisomeric mixtures into their components and components obtained hereby
FR7318126A FR2185406B1 (en:Method) 1972-05-19 1973-05-18
BE131271A BE799728A (fr) 1972-05-19 1973-05-18 Procede pour la separation de steredoisomeres de certains steroides
SU1918554A SU468408A3 (ru) 1972-05-19 1973-05-18 Способ разделени стереоизомерных смесей
NLAANVRAGE7306979,A NL175917C (nl) 1972-05-19 1973-05-18 Werkwijze voor het splitsen van isomere mengsels van steroiden, werkwijze voor het bereiden van een farmaceutisch preparaat en aldus verkregen gevormd farmaceutisch preparaat.
JP5623473A JPS547794B2 (en:Method) 1972-05-19 1973-05-19
US05/629,390 US3992534A (en) 1972-05-19 1975-11-06 Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US05/629,493 US3996359A (en) 1972-05-19 1975-11-06 Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
KE2969A KE2969A (en) 1972-05-19 1979-06-20 A process for the separation of sterioisomeric mixtures of steroid acetalsinto, their components and components obtained thereby
HK490/79A HK49079A (en) 1972-05-19 1979-07-19 A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (en:Method) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
SE378110B true SE378110B (en:Method) 1975-08-18

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7206645A SE378110B (en:Method) 1972-05-19 1972-05-19

Country Status (17)

Country Link
US (1) US3928326A (en:Method)
JP (1) JPS547794B2 (en:Method)
BE (1) BE799728A (en:Method)
CA (1) CA1003402A (en:Method)
CY (1) CY1012A (en:Method)
DE (1) DE2323216C3 (en:Method)
DK (1) DK133249C (en:Method)
FI (1) FI50711C (en:Method)
FR (1) FR2185406B1 (en:Method)
GB (1) GB1428416A (en:Method)
HK (1) HK49079A (en:Method)
IL (1) IL42154A (en:Method)
KE (1) KE2969A (en:Method)
NL (1) NL175917C (en:Method)
SE (1) SE378110B (en:Method)
SU (1) SU468408A3 (en:Method)
ZA (1) ZA732956B (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
BR9307746A (pt) * 1993-01-08 1995-11-14 Astra Ab Derivados de esteróides especificos para otratamento de cólon e ileo
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7750151B2 (en) 2004-04-09 2010-07-06 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
HRP20120361T1 (hr) 2007-03-14 2012-05-31 Ranbaxy Laboratories Limited DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
UA108858C2 (xx) * 2009-09-11 2015-06-25 Похідні ізоксалідину
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CN104736535B (zh) 2012-08-24 2017-12-19 德州大学系统董事会 用于治疗疾病的hif活性的杂环调节剂
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
CN110291097A (zh) 2016-11-08 2019-09-27 里珍纳龙药品有限公司 类固醇类化合物及其蛋白质-偶联物
WO2018213077A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
KR102786381B1 (ko) 2018-01-08 2025-03-26 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 항체-접합체
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230108452A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
IL319241A (en) 2022-09-02 2025-04-01 Merck Sharp & Dohme Llc Pharmaceutical preparations of topoisomerase-1 inhibitors of extacan derivatives, and their uses
TW202432099A (zh) 2022-10-25 2024-08-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途
JP2025522671A (ja) 2022-12-14 2025-07-17 メルク・シャープ・アンド・ドーム・エルエルシー アウリスタチンリンカー－ペイロード、医薬組成物及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Also Published As

Publication number Publication date
US3928326A (en) 1975-12-23
FI50711B (en:Method) 1976-03-01
FR2185406A1 (en:Method) 1974-01-04
FR2185406B1 (en:Method) 1976-12-31
DE2323216A1 (de) 1973-11-29
JPS547794B2 (en:Method) 1979-04-10
NL7306979A (en:Method) 1973-11-21
SU468408A3 (ru) 1975-04-25
NL175917B (nl) 1984-08-16
GB1428416A (en) 1976-03-17
NL175917C (nl) 1985-01-16
CA1003402A (en) 1977-01-11
JPS4941379A (en:Method) 1974-04-18
ZA732956B (en) 1974-04-24
DK133249B (da) 1976-04-12
DE2323216B2 (de) 1977-11-03
DK133249C (da) 1976-09-13
CY1012A (en) 1979-11-23
AU5525273A (en) 1974-11-07
FI50711C (fi) 1976-06-10
HK49079A (en) 1979-07-27
KE2969A (en) 1979-07-20
DE2323216C3 (de) 1978-06-22
IL42154A0 (en) 1973-07-30
IL42154A (en) 1976-12-31
BE799728A (fr) 1973-09-17

Similar Documents

Publication Publication Date Title
FR2185406B1 (en:Method)
CS150338B1 (en:Method)
CS153682B1 (en:Method)
CS153916B1 (en:Method)
CS154479B1 (en:Method)
CS154482B1 (en:Method)
CH571915A5 (en:Method)
CH576317A5 (en:Method)
BG19067A1 (en:Method)
CH1001473A4 (en:Method)
CH1028272A4 (en:Method)
CH1665073A4 (en:Method)
CH225172A4 (en:Method)
CH545533A (en:Method)
CH561488A5 (en:Method)
CH564834A5 (en:Method)
CH565023A5 (en:Method)
CH565094A5 (en:Method)
CH565508A5 (en:Method)
CH566685A5 (en:Method)
CH566778A5 (en:Method)
CH569273A5 (en:Method)
CH571879A5 (en:Method)
CH571898A5 (en:Method)
CH577491A5 (en:Method)